<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:36:54Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10841916" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10841916</identifier>
        <datestamp>2024-02-05</datestamp>
        <setSpec>nihpa</setSpec>
        <setSpec>pmc-open</setSpec>
        <setSpec>manuscript</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-journal-id">9007422</journal-id>
              <journal-id journal-id-type="pubmed-jr-id">2306</journal-id>
              <journal-id journal-id-type="nlm-ta">Leuk Lymphoma</journal-id>
              <journal-id journal-id-type="iso-abbrev">Leuk Lymphoma</journal-id>
              <journal-title-group>
                <journal-title>Leukemia &amp; lymphoma</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1042-8194</issn>
              <issn pub-type="epub">1029-2403</issn>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10841916</article-id>
              <article-id pub-id-type="pmcid">PMC10841916</article-id>
              <article-id pub-id-type="pmc-uid">10841916</article-id>
              <article-id pub-id-type="pmid">36642966</article-id>
              <article-id pub-id-type="pmid">36642966</article-id>
              <article-id pub-id-type="doi">10.1080/10428194.2022.2164194</article-id>
              <article-id pub-id-type="manuscript">nihpa1953119</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with <italic toggle="yes">CREBBP</italic> or <italic toggle="yes">EP300</italic> mutations: an open label phase II study</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5297-9685</contrib-id>
                  <name>
                    <surname>Qualls</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3001-4898</contrib-id>
                  <name>
                    <surname>Noy</surname>
                    <given-names>Ariela</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8364-6816</contrib-id>
                  <name>
                    <surname>Straus</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4581-3721</contrib-id>
                  <name>
                    <surname>Matasar</surname>
                    <given-names>Matthew</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9189-3152</contrib-id>
                  <name>
                    <surname>Moskowitz</surname>
                    <given-names>Craig</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Seshan</surname>
                    <given-names>Venkatraman</given-names>
                  </name>
                  <xref rid="A5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6576-5256</contrib-id>
                  <name>
                    <surname>Dogan</surname>
                    <given-names>Ahmet</given-names>
                  </name>
                  <xref rid="A6" ref-type="aff">f</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9541-8666</contrib-id>
                  <name>
                    <surname>Salles</surname>
                    <given-names>Gilles</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0001-4133</contrib-id>
                  <name>
                    <surname>Younes</surname>
                    <given-names>Anas</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="FN1" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1403-6883</contrib-id>
                  <name>
                    <surname>Zelenetz</surname>
                    <given-names>Andrew D.</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9036-9463</contrib-id>
                  <name>
                    <surname>Lee Batlevi</surname>
                    <given-names>Connie</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                  <xref rid="FN2" ref-type="author-notes">†</xref>
                </contrib>
              </contrib-group>
              <aff id="A1"><label>a</label>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
              <aff id="A2"><label>b</label>Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
              <aff id="A3"><label>c</label>Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA</aff>
              <aff id="A4"><label>d</label>Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA</aff>
              <aff id="A5"><label>e</label>Department of Epidemiology and Biostatistics, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
              <aff id="A6"><label>f</label>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
              <author-notes>
                <fn fn-type="present-address" id="FN1">
                  <label>*</label>
                  <p id="P1">Present address: AstraZeneca, Wilmington, DE, USA.</p>
                </fn>
                <fn fn-type="present-address" id="FN2">
                  <label>†</label>
                  <p id="P2">Present address: Genentech, San Francisco, CA, USA.</p>
                </fn>
                <fn fn-type="con" id="FN3">
                  <p id="P3">Author contributions</p>
                  <p id="P4">D.Q. and C.B. collected and analyzed data and wrote the manuscript. C.B. and A.Z. designed the study. G.S. contributed to data analysis, and reviewed and edited the manuscript.</p>
                </fn>
                <corresp id="CR1"><bold>CONTACT</bold> Connie Lee Batlevi <email>conniewclee@gmail.com</email> Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA</corresp>
              </author-notes>
              <pub-date pub-type="nihms-submitted">
                <day>31</day>
                <month>12</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>3</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>15</day>
                <month>1</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>05</day>
                <month>2</month>
                <year>2024</year>
              </pub-date>
              <volume>64</volume>
              <issue>3</issue>
              <fpage>738</fpage>
              <lpage>741</lpage>
              <permissions>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.</license-p>
                </license>
              </permissions>
            </article-meta>
          </front>
          <body>
            <p id="P5">Deregulation of normal epigenetic regulatory mechanisms, including histone acetylation, is increasingly recognized as a major driver in lymphoma, particularly germinal center origin non-Hodgkin lymphomas like follicular lymphoma (FL) and the germinal center subtype of diffuse large B-cell lymphoma (DLBCL) [<xref rid="R1" ref-type="bibr">1</xref>]. Many studies have aimed to target these derangements using histone deacetylase (HDAC) inhibitors. However, prior studies of HDAC inhibitors in FL and DLBCL, including mocetinostat [<xref rid="R2" ref-type="bibr">2</xref>], vorinostat [<xref rid="R3" ref-type="bibr">3</xref>–<xref rid="R5" ref-type="bibr">5</xref>], panobinostat [<xref rid="R6" ref-type="bibr">6</xref>], and abexinostat [<xref rid="R7" ref-type="bibr">7</xref>], have shown heterogeneous response rates, from 11% to 64% in FL and 6% to 28% in DLBCL, and limited durations of response.</p>
            <p id="P6">Two of the most common mutations observed in FL and GCB DLBCL are inactivating mutations of <italic toggle="yes">CREBBP</italic> and <italic toggle="yes">EP300</italic>. Both <italic toggle="yes">CREBBP</italic> and <italic toggle="yes">EP300</italic> serve as transcriptional coactivators to other proteins, including key tumor suppressors like TP53, while inhibiting expression of the oncogenic BCL60 [<xref rid="R8" ref-type="bibr">8</xref>–<xref rid="R15" ref-type="bibr">15</xref>]. By inhibiting HDACs that remove acetyl groups from histones, HDAC inhibitors may reestablish physiologic levels of acetylation and result in tumor death.</p>
            <p id="P7">We hypothesized that HDAC inhibition with mocetinostat would be particularly effective in lymphomas with <italic toggle="yes">CREBBP</italic> or <italic toggle="yes">EP300</italic> mutations, and designed a biomarker-driven clinical trial evaluating the efficacy of mocetinostat in patients with R/R FL or DLBCL and <italic toggle="yes">CREBBP</italic> or <italic toggle="yes">EP300</italic> mutations.</p>
            <p id="P8">We performed a phase II, open-label, single-arm clinical trial evaluating the efficacy of mocetinostat in patients with relapsed or refractory DLBCL or FL harboring mutations in <italic toggle="yes">CREBBP</italic> or <italic toggle="yes">EP300</italic>. The study was approved by the Institutional Review Board of Memorial Sloan Kettering Cancer Center, and registered at <ext-link xlink:href="http://www.clinicaltrials.gov" ext-link-type="uri">www.clinicaltrials.gov</ext-link> (<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02282358" ext-link-type="uri">NCT02282358</ext-link>). Patients with FL or DLBCL which was relapsed or refractory to two prior lines of treatment, good performance status, and adequate bone marrow and organ function were eligible for enrollment. Genetic testing was performed using any CLIA approved next-generation sequencing (NGS) platform, which was most commonly Foundation One Heme or MSK IMPACT based testing, with the latter utilizing normal tissue (nails or saliva) used as a germline comparison [<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref>]. To be eligible, sequencing had to confirm the presence of <italic toggle="yes">CREBBP</italic> or <italic toggle="yes">EP300</italic> mutation (deletion, frameshift, nonsense, or missense), known to affect the histone acetyltransferase function of CREBBP or EP300, based on previously published data and/or the COSMIC database [<xref rid="R1" ref-type="bibr">1</xref>].</p>
            <p id="P9">Patients were treated with mocetinostat 70 mg orally three times per week on a 28-day schedule in cycle 1. The dose was escalated in cycle 2 to 90 mg orally three times per week in the absence of grade 3 or higher drug related toxicities. Treatment was continued until disease progression, intolerable toxicity, or death.</p>
            <p id="P10">The primary outcome of interest was efficacy as defined by overall response rate (ORR) at one year. Secondary objectives included assessing the event-free survival (EFS), duration of response (DOR), and safety and tolerability of mocetinostat. Exploratory assessments included correlation of Myc and Bcl-2 positivity with treatment response, assessment of mechanisms of resistance, and evaluation of T cell activation and exhaustion in peripheral blood.</p>
            <p id="P11">From 29 October 2014 to 5 April 2017, we screened 102 patients with FL and DLBCL using NGS of tumor samples. Of these, 27 patients harbored mutations in <italic toggle="yes">CREBBP</italic> and/or <italic toggle="yes">EP300</italic>. Of the 27 patients harboring a <italic toggle="yes">CREBBP</italic> or <italic toggle="yes">EP300</italic> mutation, seven patients were enrolled and treated.</p>
            <p id="P12">Five patients had FL grade 1–3A, and two patients had transformed DLBCL from FL (<xref rid="T1" ref-type="table">Table 1</xref>). Six of seven patients had <italic toggle="yes">CREBBP</italic> mutations, and one patient with FL had an <italic toggle="yes">EP300</italic> mutation (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 1</xref>). Of five evaluable patients, four had <italic toggle="yes">BCL2</italic> translocations. Median age was 67 (range 49–83), and five (71%) were male. Six (86%) were white and one (14%) was Asian. ECOG performance status was 0 in three patients and one in four patients. In patients with FL, FLIPI scores were 0–1 in two patients, 2 (moderate risk) in one patient, and 3–5 (high risk) in two patients. Both patients with DLBCL had IPI scores of 3. Patients had received a median of 4 prior lines of therapy (range 3–9); all had received prior anthracycline-based chemotherapy and anti-CD20 monoclonal antibody therapy, and three (43%) had received prior radiation. None had received prior autologous stem cell transplant.</p>
            <p id="P13">Of seven patients treated with mocetinostat, one achieved a partial remission and remained on treatment for 12.9 months, with a 1-year ORR of 14% (<xref rid="F1" ref-type="fig">Figure 1</xref>). Two patients had stable disease as best response and remained on treatment for 17.5 and 7.3 months; the remaining three response-evaluable patients had disease progression. One patient withdrew therapy for toxicity prior to response assessment. Median PFS was 4.6 months, and median EFS was 4.6 months.</p>
            <p id="P14">The most common adverse events were diarrhea (grade 1–2 in 57%, grade 3 in 14%), fatigue (grade 1 in 57%), rash (grade 1 in 57%), and nausea (grade 1 in 43%). Grade 3–4 hematologic events were grade 3 lymphopenia in one patient (14%) and grade 4 neutropenia in one patient (14%) without any episodes of neutropenic fever. One patient suffered grade 4 enterocolitis complicated by septic shock, hemolytic uremic syndrome, acute renal failure, and respiratory failure, reported as unrelated to study drug, 14 days after initiating therapy; treatment was discontinued due to ongoing comorbidities precluding participation. One patient with stable disease discontinued therapy for persistent grade 2 diarrhea and abdominal discomfort 17.4 months after starting treatment. The other five patients (71%) discontinued treatment for progression of disease.</p>
            <p id="P15">The median time to onset of treatment-related adverse events (TRAEs) was 26 days (interquartile range, 2–53 days). The median time to onset of the most common TRAE, diarrhea, was 24 days (range, 0–53 days). No dose reductions of mocetinostat occurred; two patients had dose interruptions, one for the previously mentioned grade 4 enterocolitis, and another for grade 4 neutropenia.</p>
            <p id="P16">Enrollment was limited due to withdrawal of drug support by the sponsor.</p>
            <p id="P17">In summary, we performed a biomarker-driven clinical trial evaluating the anti-tumor activity of mocetinostat in patients with DLBCL or FL with mutations in <italic toggle="yes">CREBBP</italic> or <italic toggle="yes">EP300</italic>, which we hypothesized would have increased sensitivity to HDAC inhibitors. Study enrollment was limited and lymphoma activity was modest, with one patient achieving response to treatment, and response rates similar to those reported in an unselected cohort of patients with R/R NHL [<xref rid="R2" ref-type="bibr">2</xref>].</p>
            <p id="P18">Despite strong mechanistic rationale for the use of HDAC inhibitors in <italic toggle="yes">CREBBP</italic> and <italic toggle="yes">EP300</italic>-mutant lymphomas, limited clinical evidence to date has not clearly matched this expectation. Along with our study, subset analyses of a clinical trial of panobinostat in DLBCL showed that only 15% of <italic toggle="yes">CREBBP</italic> or <italic toggle="yes">EP300</italic>-mutant lymphomas responded to treatment, which was below the total ORR of 28% [<xref rid="R6" ref-type="bibr">6</xref>]. Likewise, in a trial of vorinostat in FL, <italic toggle="yes">CREBBP</italic> and <italic toggle="yes">EP300</italic> mutations were not associated with higher ORR or longer PFS [<xref rid="R4" ref-type="bibr">4</xref>]. It should be noted that the EZH2 inhibitor tazemetostat, another epigenetic therapy, was associated with greater response rates in FL with gain of function mutations in <italic toggle="yes">EZH2</italic>, but responses were also seen in FL without these gain of function mutations, with similar DOR in mutant and wild-type disease, suggesting that the activity of epigenetic therapies is not restricted to diseases with single aberrations [<xref rid="R18" ref-type="bibr">18</xref>].</p>
            <p id="P19">Higher response rates have been reported in other HDAC inhibitor studies. A recent trial of abexinostat in 37 patients with FL showed a response rate of 70% [<xref rid="R19" ref-type="bibr">19</xref>]. Differences may be due to patient population or the therapy itself; abexinostat is a pan-HDAC inhibitor, which may have different anti-lymphoma activity compared to the HDAC1-selective activity of mocetinostat. Molecular analysis, including <italic toggle="yes">CREBBP</italic> and <italic toggle="yes">EP300</italic> mutations, were not reported in this study.</p>
            <p id="P20">Despite modest response rates, this study demonstrates the feasibility of a molecularly targeted therapeutic approach for patients with lymphoma. Patients successfully completed clinical and molecular screening to determine eligibility and were enrolled in a timely manner. Molecular screening methods were also employed in the multicenter phase 2 trial of tazemetostat, with cohort assignment based on <italic toggle="yes">EZH2</italic> mutation status [<xref rid="R18" ref-type="bibr">18</xref>]. As our understanding of molecular pathogenesis and heterogeneity of FL and DLBCL advance, the ability to develop prospective trials using molecular testing to select patients who may be most likely to benefit will be essential. This study provides a potential platform by which to develop molecularly driven targeted and epigenetic trials in the future.</p>
            <sec sec-type="supplementary-material" id="SM1">
              <title>Supplementary Material</title>
              <supplementary-material id="SD1" position="float" content-type="local-data">
                <label>supplemental</label>
                <media xlink:href="NIHMS1953119-supplement-supplemental.pdf" id="d64e425" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="S1">
              <title>Acknowledgements</title>
              <p id="P21">The authors would like to thank the patients for their participation and contribution. We would also like to thank the Mirati research team, including James Christensen and Chuck Baum, for their discussions regarding the clinical trial concept and guidance during the study.</p>
              <sec id="S2">
                <title>Funding</title>
                <p id="P22">This clinical trial was sponsored by Memorial Sloan Kettering Cancer Center (MSK), with additional monetary and therapeutic drug support from Mirati. This research was funded in part by Core Grants as part of the MSK Lymphoma SPORE [P50 CA192937], and the NIH/NCI Cancer Center Support Grant [P30 CA008748] to MSK. Dr. Batlevi’s work has been supported by an ASCO Young Investigator Award, an ASH Clinical Scholar Award, and Dr. Qualls’s work has been supported by the Lymphoma Research Foundation Clinical Research Mentoring Program. We also thank the George L. Ohrstrom Foundation, Steven A. Greenberg Award for support of our clinical translational research.</p>
              </sec>
              <sec id="S3">
                <title>Disclosure statement</title>
                <p id="P23"><italic toggle="yes">Kumar</italic>: research support from AbbVie, Adaptive Biotechnologies, Celgene, Pharmacyclics, and Seattle Genetics; and has an advisory role with Celgene. <italic toggle="yes">A. Noy</italic>: research support from Abbvie, Cornerstone, Jannsen; honoraria from Abbvie; consultancy role Epizyme, Janssen, Morphosys, AstraZeneca, EUSA, TG therapeutics, and ADC therapeutics. <italic toggle="yes">M. Matasar</italic>: research support from Genentech, Roche, GlaxoSmithKline, Bayer, Pharmacyclics, Janssen, Rocket Medical, and Seattle Genetics; has received honoraria from Genentech, Roche, Bayer, Pharmacyclics, Janssen, Seattle Genetics, and GlaxoSmithKline; and has a consultancy role with Genentech, Bayer, Merck, Juno, Roche, Teva, Rocket Medical, and Seattle Genetics. <italic toggle="yes">G. Salles</italic>: consultancy role with AbbVie, Bayer, Beigene, BMS/Celgene, Debiopharm, Epizyme, Genentech/Roche, Genmab, Incyte, Ipsen, Janssen, Kite/Gilead, Loxo, Milteniy, Morphosys, Novartis, Rapt, Regeneron, Takeda, and Velosbio. <italic toggle="yes">A. Younes</italic>: employment at AstraZeneca. <italic toggle="yes">C.L. Batlevi</italic>: research support from Janssen, Novartis, Epizyme, Autolus, Roche, and Bayer; has received honoraria from Dava Oncology; and has a consultancy role with Skipta, Kite Pharma, MorphoSys, Bristol-Myers Squibb, Karyopharm Therapeutics, Genentech, and TG Therapeutics. D. Qualls, H.Y. Lam, K. Whiting, C. Owens, C. Nichols, J. Espleleta, S. Subzwari, E. Biggar, and V. Seshan have no conflicts of interest to disclose.</p>
              </sec>
            </ack>
            <sec sec-type="data-availability" id="S4">
              <title>Data availability statement</title>
              <p id="P24">The data that support the findings of this study are available from the corresponding author, C.B., upon reasonable request.</p>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>[1]</label>
                <mixed-citation publication-type="journal"><name><surname>Pasqualucci</surname><given-names>L</given-names></name>, <name><surname>Dominguez-Sola</surname><given-names>D</given-names></name>, <name><surname>Chiarenza</surname><given-names>A</given-names></name>, <etal/><article-title>Inactivating mutations of acetyltransferase genes in B-cell lymphoma</article-title>. <source>Nature</source>. <year>2011</year>;<volume>471</volume>(<issue>7337</issue>):<fpage>189</fpage>–<lpage>195</lpage>.<pub-id pub-id-type="pmid">21390126</pub-id>
</mixed-citation>
              </ref>
              <ref id="R2">
                <label>[2]</label>
                <mixed-citation publication-type="journal"><name><surname>Batlevi</surname><given-names>CL</given-names></name>, <name><surname>Crump</surname><given-names>M</given-names></name>, <name><surname>Andreadis</surname><given-names>C</given-names></name>, <etal/><article-title>A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma</article-title>. <source>Br J Haematol</source>. <year>2017</year>;<volume>178</volume>(<issue>3</issue>):<fpage>434</fpage>–<lpage>441</lpage>.<pub-id pub-id-type="pmid">28440559</pub-id>
</mixed-citation>
              </ref>
              <ref id="R3">
                <label>[3]</label>
                <mixed-citation publication-type="journal"><name><surname>Crump</surname><given-names>M</given-names></name>, <name><surname>Coiffier</surname><given-names>B</given-names></name>, <name><surname>Jacobsen</surname><given-names>ED</given-names></name>, <etal/><article-title>Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma</article-title>. <source>Ann Oncol</source>. <year>2008</year>;<volume>19</volume>(<issue>5</issue>):<fpage>964</fpage>–<lpage>969</lpage>.<pub-id pub-id-type="pmid">18296419</pub-id>
</mixed-citation>
              </ref>
              <ref id="R4">
                <label>[4]</label>
                <mixed-citation publication-type="journal"><name><surname>Ogura</surname><given-names>M</given-names></name>, <name><surname>Ando</surname><given-names>K</given-names></name>, <name><surname>Suzuki</surname><given-names>T</given-names></name>, <etal/><article-title>A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma</article-title>. <source>Br J Haematol</source>. <year>2014</year>;<volume>165</volume>(<issue>6</issue>):<fpage>768</fpage>–<lpage>776</lpage>.<pub-id pub-id-type="pmid">24617454</pub-id>
</mixed-citation>
              </ref>
              <ref id="R5">
                <label>[5]</label>
                <mixed-citation publication-type="journal"><name><surname>Kirschbaum</surname><given-names>M</given-names></name>, <name><surname>Frankel</surname><given-names>P</given-names></name>, <name><surname>Popplewell</surname><given-names>L</given-names></name>, <etal/><article-title>Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphoma</article-title>. <source>J Clin Oncol</source>. <year>2011</year>;<volume>29</volume>(<issue>9</issue>):<fpage>1198</fpage>–<lpage>1203</lpage>.<pub-id pub-id-type="pmid">21300924</pub-id>
</mixed-citation>
              </ref>
              <ref id="R6">
                <label>[6]</label>
                <mixed-citation publication-type="journal"><name><surname>Assouline</surname><given-names>SE</given-names></name>, <name><surname>Nielsen</surname><given-names>TH</given-names></name>, <name><surname>Yu</surname><given-names>S</given-names></name>, <etal/><article-title>Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma</article-title>. <source>Blood</source>. <year>2016</year>;<volume>128</volume>(<issue>2</issue>):<fpage>185</fpage>–<lpage>194</lpage>.<pub-id pub-id-type="pmid">27166360</pub-id>
</mixed-citation>
              </ref>
              <ref id="R7">
                <label>[7]</label>
                <mixed-citation publication-type="journal"><name><surname>Ribrag</surname><given-names>V</given-names></name>, <name><surname>Kim</surname><given-names>WS</given-names></name>, <name><surname>Bouabdallah</surname><given-names>R</given-names></name>, <etal/><article-title>Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study</article-title>. <source>Haematologica</source>. <year>2017</year>;<volume>102</volume>(<issue>5</issue>):<fpage>903</fpage>–<lpage>909</lpage>.<pub-id pub-id-type="pmid">28126962</pub-id>
</mixed-citation>
              </ref>
              <ref id="R8">
                <label>[8]</label>
                <mixed-citation publication-type="journal"><name><surname>Kalkhoven</surname><given-names>E</given-names></name>. <article-title>CBP and p300: HATs for different occasions</article-title>. <source>Biochem Pharmacol</source>. <year>2004</year>;<volume>68</volume>(<issue>6</issue>):<fpage>1145</fpage>–<lpage>1155</lpage>.<pub-id pub-id-type="pmid">15313412</pub-id>
</mixed-citation>
              </ref>
              <ref id="R9">
                <label>[9]</label>
                <mixed-citation publication-type="journal"><name><surname>Goodman</surname><given-names>RH</given-names></name>, <name><surname>Smolik</surname><given-names>S</given-names></name>. <article-title>CBP/p300 in cell growth, transformation, and development</article-title>. <source>Genes Dev</source>. <year>2000</year>;<volume>14</volume>(<issue>13</issue>):<fpage>1553</fpage>–<lpage>1577</lpage>.<pub-id pub-id-type="pmid">10887150</pub-id>
</mixed-citation>
              </ref>
              <ref id="R10">
                <label>[10]</label>
                <mixed-citation publication-type="journal"><name><surname>Ogryzko</surname><given-names>VV</given-names></name>, <name><surname>Schiltz</surname><given-names>RL</given-names></name>, <name><surname>Russanova</surname><given-names>V</given-names></name>, <etal/><article-title>The transcriptional coactivators p300 and CBP are histone acetyltransferases</article-title>. <source>Cell</source>. <year>1996</year>;<volume>87</volume>(<issue>5</issue>):<fpage>953</fpage>–<lpage>959</lpage>.<pub-id pub-id-type="pmid">8945521</pub-id>
</mixed-citation>
              </ref>
              <ref id="R11">
                <label>[11]</label>
                <mixed-citation publication-type="journal"><name><surname>Bannister</surname><given-names>AJ</given-names></name>, <name><surname>Kouzarides</surname><given-names>T</given-names></name>. <article-title>The CBP co-activator is a histone acetyltransferase</article-title>. <source>Nature</source>. <year>1996</year>;<volume>384</volume>(<issue>6610</issue>):<fpage>641</fpage>–<lpage>643</lpage>.<pub-id pub-id-type="pmid">8967953</pub-id>
</mixed-citation>
              </ref>
              <ref id="R12">
                <label>[12]</label>
                <mixed-citation publication-type="journal"><name><surname>Lill</surname><given-names>NL</given-names></name>, <name><surname>Grossman</surname><given-names>SR</given-names></name>, <name><surname>Ginsberg</surname><given-names>D</given-names></name>, <etal/><article-title>Binding and modulation of p53 by p300/CBP coactivators</article-title>. <source>Nature</source>. <year>1997</year>;<volume>387</volume>(<issue>6635</issue>):<fpage>823</fpage>–<lpage>827</lpage>.<pub-id pub-id-type="pmid">9194565</pub-id>
</mixed-citation>
              </ref>
              <ref id="R13">
                <label>[13]</label>
                <mixed-citation publication-type="journal"><name><surname>Gu</surname><given-names>W</given-names></name>, <name><surname>Shi</surname><given-names>XL</given-names></name>, <name><surname>Roeder</surname><given-names>RG</given-names></name>. <article-title>Synergistic activation of transcription by CBP and p53</article-title>. <source>Nature</source>. <year>1997</year>;<volume>387</volume>(<issue>6635</issue>):<fpage>819</fpage>–<lpage>823</lpage>.<pub-id pub-id-type="pmid">9194564</pub-id>
</mixed-citation>
              </ref>
              <ref id="R14">
                <label>[14]</label>
                <mixed-citation publication-type="journal"><name><surname>Bereshchenko</surname><given-names>OR</given-names></name>, <name><surname>Gu</surname><given-names>W</given-names></name>, <name><surname>Dalla-Favera</surname><given-names>R</given-names></name>. <article-title>Acetylation inactivates the transcriptional repressor BCL6</article-title>. <source>Nat Genet</source>. <year>2002</year>;<volume>32</volume>(<issue>4</issue>):<fpage>606</fpage>—<lpage>613</lpage>.<pub-id pub-id-type="pmid">12402037</pub-id>
</mixed-citation>
              </ref>
              <ref id="R15">
                <label>[15]</label>
                <mixed-citation publication-type="journal"><name><surname>Phan</surname><given-names>RT</given-names></name>, <name><surname>Dalla-Favera</surname><given-names>R</given-names></name>. <article-title>The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells</article-title>. <source>Nature</source>. <year>2004</year>;<volume>432</volume>(<issue>7017</issue>):<fpage>635</fpage>–<lpage>639</lpage>.<pub-id pub-id-type="pmid">15577913</pub-id>
</mixed-citation>
              </ref>
              <ref id="R16">
                <label>[16]</label>
                <mixed-citation publication-type="journal"><name><surname>Cheng</surname><given-names>DT</given-names></name>, <name><surname>Mitchell</surname><given-names>TN</given-names></name>, <name><surname>Zehir</surname><given-names>A</given-names></name>, <etal/><article-title>Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology</article-title>. <source>J Mol Diagn</source>. <year>2015</year>;<volume>17</volume>(<issue>3</issue>):<fpage>251</fpage> —<lpage>264</lpage>.<pub-id pub-id-type="pmid">25801821</pub-id>
</mixed-citation>
              </ref>
              <ref id="R17">
                <label>[17]</label>
                <mixed-citation publication-type="journal"><name><surname>Ptashkin</surname><given-names>RN</given-names></name>, <name><surname>Ewalt</surname><given-names>MD</given-names></name>, <name><surname>Jayakumaran</surname><given-names>G</given-names></name>, <etal/><article-title>Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing</article-title>. <source>medRxiv</source>; <year>2022</year>.</mixed-citation>
              </ref>
              <ref id="R18">
                <label>[18]</label>
                <mixed-citation publication-type="journal"><name><surname>Morschhauser</surname><given-names>F</given-names></name>, <name><surname>Tilly</surname><given-names>H</given-names></name>, <name><surname>Chaidos</surname><given-names>A</given-names></name>, <etal/><article-title>Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial</article-title>. <source>Lancet Oncol</source>. <year>2020</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1433</fpage>—<lpage>1442</lpage>.<pub-id pub-id-type="pmid">33035457</pub-id>
</mixed-citation>
              </ref>
              <ref id="R19">
                <label>[19]</label>
                <mixed-citation publication-type="journal"><name><surname>Gui</surname><given-names>L</given-names></name>, <name><surname>Cheng</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>H</given-names></name>, <etal/><article-title>Interim results of a phase II multicenter study with the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory follicular lymphoma</article-title>. <source>J Clin Oncol</source>. <year>2022</year>;<volume>40</volume>(<issue>16_Suppl</issue>.):<fpage>7513</fpage>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig position="float" id="F1">
              <label>Figure 1.</label>
              <caption>
                <p id="P25">Swimmer plot of all seven treated patients. DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; CR: complete response; PR: partial response; SD: stable disease; POD: progression of disease.</p>
              </caption>
              <graphic xlink:href="nihms-1953119-f0001" position="float"/>
            </fig>
            <table-wrap position="float" id="T1" orientation="landscape">
              <label>Table 1.</label>
              <caption>
                <p id="P26">Patient characteristics and outcomes.</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="bottom" rowspan="1" colspan="1">Patient ID</th>
                    <th align="center" valign="bottom" rowspan="1" colspan="1">Sex</th>
                    <th align="center" valign="bottom" rowspan="1" colspan="1">Age</th>
                    <th align="center" valign="bottom" rowspan="1" colspan="1">Diagnosis</th>
                    <th align="center" valign="bottom" rowspan="1" colspan="1">Mutation</th>
                    <th align="center" valign="bottom" rowspan="1" colspan="1">VAF</th>
                    <th align="center" valign="bottom" rowspan="1" colspan="1">BCL2 translocation</th>
                    <th align="center" valign="bottom" rowspan="1" colspan="1">Stage</th>
                    <th align="center" valign="bottom" rowspan="1" colspan="1">IPI/FLIPI</th>
                    <th align="center" valign="bottom" rowspan="1" colspan="1">Prior treatment lines</th>
                    <th align="center" valign="bottom" rowspan="1" colspan="1">Best response</th>
                    <th align="center" valign="bottom" rowspan="1" colspan="1">Treatment duration (months)</th>
                    <th align="center" valign="bottom" rowspan="1" colspan="1">PFS (months)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">F</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">74</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">FL</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">CREBBP</italic> Y1450N</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">POD</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">  1.9</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">  1.9</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">M</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">49</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">FL (Grade 3B)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">CREBBP</italic> K1042*, loss exon 19–30</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.19</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">POD</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">  1.8</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">  1.8</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">M</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">77</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">DLBCL</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">CREBBP</italic> N1644fs*100, V1371D</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.12, 0.21</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">POD</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">  1.4</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">  1.4</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">M</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">56</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">FL</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">CREBBP</italic> Y1433N (c.4297T &gt; A)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.2</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">SD</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">17.8</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">NE</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">M</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">67</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">DLBCL</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">CREBBP</italic> S1680del</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.65</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">No</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">7</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">PR</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">12.8</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">13.1</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">F</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">83</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">FL</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">CREBBP</italic> S1680del</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.76</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">Unknown</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">9</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">POD</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">  0.3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">NE</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">7</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">M</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">64</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">FL</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">EP300</italic> P1452L</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.42</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">Unknown</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">SD</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">  7.4</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">  7.4</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN1">
                  <p id="P27">VAF: variant allele frequency; IPI: international prognostic index; FLIPI: follicular lymphoma international prognostic index; PFS: progression-free survival; FL: follicular lymphoma; DLBCL: diffuse large B-cell lymphoma; PR: partial response; SD: stable disease; POD: progression of disease; NE: not evaluable.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
